All In Biotech

Free tool

FAERS Monitor: Abrilada

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761118 or its brand name (Abrilada, Adalimumab-Afzb). Reports on generic versions are filed under their own applications.

Reports

2,683

Serious

2,295

86% of reports

Hospitalization

486

Death reported

123

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use824
  • condition aggravated636
  • drug ineffective346
  • fatigue262
  • arthralgia229
  • pain198
  • injection site pain173
  • drug dose omission by device145
  • nausea142
  • abdominal pain139
  • diarrhoea135
  • headache129
  • inappropriate schedule of product administration126
  • device mechanical issue122
  • malaise117

Reports by year received

View as table
YearReports
20202
20212
2022340
2023752
2024794
2025570
2026223

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,476 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
device mechanical issueSignal12270.459.18,206
condition aggravatedSignal63616.415.49,317
drug dose omission by deviceSignal14514.512.41,818
off label useSignal8247.47.04,734
inappropriate schedule of product administrationSignal1265.54.6461
abdominal painSignal1394.74.0404
injection site painSignal1734.43.8461
arthralgiaSignal2294.33.8592
fatigueSignal2622.62.4275
painSignal1982.52.2187
malaiseSignal1172.11.867
drug ineffectiveSignal3462.11.9200
diarrhoea1351.61.434
headache1291.61.430
nausea1421.41.217

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.